Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release.

Szot C, Saha S, Zhang XM, Zhu Z, Hilton MB, Morris K, Seaman S, Dunleavey JM, Hsu KS, Yu GJ, Morris H, Swing DA, Haines DC, Wang Y, Hwang J, Feng Y, Welsch D, DeCrescenzo G, Chaudhary A, Zudaire E, Dimitrov DS, St Croix B.

J Clin Invest. 2018 Jul 2;128(7):2927-2943. doi: 10.1172/JCI120481. Epub 2018 Jun 4.

2.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.

3.

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).

Germann UA, Furey BF, Markland W, Hoover RR, Aronov AM, Roix JJ, Hale M, Boucher DM, Sorrell DA, Martinez-Botella G, Fitzgibbon M, Shapiro P, Wick MJ, Samadani R, Meshaw K, Groover A, DeCrescenzo G, Namchuk M, Emery CM, Saha S, Welsch DJ.

Mol Cancer Ther. 2017 Nov;16(11):2351-2363. doi: 10.1158/1535-7163.MCT-17-0456. Epub 2017 Sep 22.

4.

Characterization of polycrystalline lead oxide for application in direct conversion X-ray detectors.

Semeniuk O, Grynko O, Decrescenzo G, Juska G, Wang K, Reznik A.

Sci Rep. 2017 Aug 17;7(1):8659. doi: 10.1038/s41598-017-09168-3.

5.

Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.

Seaman S, Zhu Z, Saha S, Zhang XM, Yang MY, Hilton MB, Morris K, Szot C, Morris H, Swing DA, Tessarollo L, Smith SW, Degrado S, Borkin D, Jain N, Scheiermann J, Feng Y, Wang Y, Li J, Welsch D, DeCrescenzo G, Chaudhary A, Zudaire E, Klarmann KD, Keller JR, Dimitrov DS, St Croix B.

Cancer Cell. 2017 Apr 10;31(4):501-515.e8. doi: 10.1016/j.ccell.2017.03.005.

6.

Evaluation of 1-(2-deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU) as an ex vivo bacterial detection agent.

Tung D, DeCrescenzo G, Welsch D, Cheung PH, Bettegowda C, Saha S.

World J Microbiol Biotechnol. 2014 Nov;30(11):3003-10. doi: 10.1007/s11274-014-1709-x. Epub 2014 Aug 2.

PMID:
25085723
7.
8.

Electroded avalanche amorphous selenium (a-Se) photosensor.

Bubon O, Decrescenzo G, Zhao W, Ohkawa Y, Miyakawa K, Matsubara T, Kikuchi K, Tanioka K, Kubota M, Rowlands JA, Reznik A.

Curr Appl Phys. 2012 May;12(3):983-988.

9.

L-glutamine is a key parameter in the immunosuppression phenomenon.

Hammami I, Chen J, Bronte V, DeCrescenzo G, Jolicoeur M.

Biochem Biophys Res Commun. 2012 Sep 7;425(4):724-9. doi: 10.1016/j.bbrc.2012.07.139. Epub 2012 Aug 1.

PMID:
22885179
10.

Amorphous and polycrystalline photoconductors for direct conversion flat panel x-ray image sensors.

Kasap S, Frey JB, Belev G, Tousignant O, Mani H, Greenspan J, Laperriere L, Bubon O, Reznik A, DeCrescenzo G, Karim KS, Rowlands JA.

Sensors (Basel). 2011;11(5):5112-57. doi: 10.3390/s110505112. Epub 2011 May 9. Review.

11.

Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretion.

Roix JJ, DeCrescenzo GA, Cheung PH, Ciallella JR, Sulpice T, Saha S, Halse R.

Diabetes Obes Metab. 2012 Apr;14(4):329-34. doi: 10.1111/j.1463-1326.2011.01529.x. Epub 2011 Dec 27.

PMID:
22059694
12.

A solid-state amorphous selenium avalanche technology for low photon flux imaging applications.

Wronski MM, Zhao W, Reznik A, Tanioka K, DeCrescenzo G, Rowlands JA.

Med Phys. 2010 Sep;37(9):4982-5.

13.

Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.

Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J.

J Med Chem. 2010 Sep 23;53(18):6653-80. doi: 10.1021/jm100669j.

PMID:
20726512
14.

MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.

Kolodziej SA, Hockerman SL, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Stehle N, Swearingen C, Becker DP.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3561-4. doi: 10.1016/j.bmcl.2010.04.111. Epub 2010 Apr 28.

PMID:
20529685
15.

Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.

Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3557-60. doi: 10.1016/j.bmcl.2010.04.130. Epub 2010 May 23.

PMID:
20529684
16.

Effect of repeated x-ray exposure on the resolution of amorphous selenium based x-ray imagers.

Kabir MZ, Chowdhury L, DeCrescenzo G, Tousignant O, Kasap SO, Rowlands JA.

Med Phys. 2010 Mar;37(3):1339-49.

17.

Closed bore XMR (CBXMR) systems for aortic valve replacement: active magnetic shielding of x-ray tubes.

Bracken JA, DeCrescenzo G, Komljenovic P, Lillaney PV, Fahrig R, Rowlands JA.

Med Phys. 2009 May;36(5):1717-26.

18.

Physiochemical drug properties associated with in vivo toxicological outcomes.

Hughes JD, Blagg J, Price DA, Bailey S, Decrescenzo GA, Devraj RV, Ellsworth E, Fobian YM, Gibbs ME, Gilles RW, Greene N, Huang E, Krieger-Burke T, Loesel J, Wager T, Whiteley L, Zhang Y.

Bioorg Med Chem Lett. 2008 Sep 1;18(17):4872-5. doi: 10.1016/j.bmcl.2008.07.071. Epub 2008 Jul 24.

PMID:
18691886
19.

Preparation and characterization of new anti-PSMA monoclonal antibodies with potential clinical use.

Moffett S, Mélançon D, DeCrescenzo G, St-Pierre C, Deschénes F, Saragovi HU, Gold P, Cuello AC.

Hybridoma (Larchmt). 2007 Dec;26(6):363-72.

PMID:
18158780
20.

The dependence of the modulation transfer function on the blocking layer thickness in amorphous selenium x-ray detectors.

Hunter DM, Belev G, DeCrescenzo G, Kasap SO, Mainprize JG, Rowlands JA, Smith C, Tümer T, Verpakhovski V, Yin S, Yaffe MJ.

Med Phys. 2007 Aug;34(8):3358-73.

PMID:
17879799
21.
22.

Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy.

Becker DP, Villamil CI, Barta TE, Bedell LJ, Boehm TL, Decrescenzo GA, Freskos JN, Getman DP, Hockerman S, Heintz R, Howard SC, Li MH, McDonald JJ, Carron CP, Funckes-Shippy CL, Mehta PP, Munie GE, Swearingen CA.

J Med Chem. 2005 Oct 20;48(21):6713-30.

PMID:
16220987
23.

Performance of a static-anode/flat-panel x-ray fluoroscopy system in a diagnostic strength magnetic field: a truly hybrid x-ray/MR imaging system.

Fahrig R, Wen Z, Ganguly A, DeCrescenzo G, Rowlands JA, Stevens GM, Saunders RF, Pelc NJ.

Med Phys. 2005 Jun;32(6):1775-84.

PMID:
16013735
24.

Ghosting caused by bulk charge trapping in direct conversion flat-panel detectors using amorphous selenium.

Zhao W, DeCrescenzo G, Kasap SO, Rowlands JA.

Med Phys. 2005 Feb;32(2):488-500.

PMID:
15789596
25.

alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.

Becker DP, DeCrescenzo G, Freskos J, Getman DP, Hockerman SL, Li M, Mehta P, Munie GE, Swearingen C.

Bioorg Med Chem Lett. 2001 Oct 22;11(20):2723-5.

PMID:
11591510
26.

alpha-Amino-beta-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1.

Becker DP, Barta TE, Bedell L, DeCrescenzo G, Freskos J, Getman DP, Hockerman SL, Li M, Mehta P, Mischke B, Munie GE, Swearingen C, Villamil CI.

Bioorg Med Chem Lett. 2001 Oct 22;11(20):2719-22.

PMID:
11591509
27.

Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols.

Freskos JN, Mischke BV, DeCrescenzo GA, Heintz R, Getman DP, Howard SC, Kishore NN, McDonald JJ, Munie GE, Rangwala S, Swearingen CA, Voliva C, Welsch DJ.

Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.

PMID:
10230616
28.

SC-52151, a novel inhibitor of the human immunodeficiency virus protease.

Bryant M, Getman D, Smidt M, Marr J, Clare M, Dillard R, Lansky D, DeCrescenzo G, Heintz R, Houseman K, et al.

Antimicrob Agents Chemother. 1995 Oct;39(10):2229-34.

29.

Inhibitors of HIV-1 protease containing the novel and potent (R)-(hydroxyethyl)sulfonamide isostere.

Vazquez ML, Bryant ML, Clare M, DeCrescenzo GA, Doherty EM, Freskos JN, Getman DP, Houseman KA, Julien JA, Kocan GP, et al.

J Med Chem. 1995 Feb 17;38(4):581-4. No abstract available.

PMID:
7861404
30.

Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere.

Getman DP, DeCrescenzo GA, Heintz RM, Reed KL, Talley JJ, Bryant ML, Clare M, Houseman KA, Marr JJ, Mueller RA, et al.

J Med Chem. 1993 Jan 22;36(2):288-91. No abstract available.

PMID:
8423599
31.

X-ray imaging using amorphous selenium: determination of x-ray sensitivity by pulse height spectroscopy.

Rowlands JA, DeCrescenzo G, Araj N.

Med Phys. 1992 Jul-Aug;19(4):1065-9.

PMID:
1518469
32.

Wiener noise power spectra of radiological television systems using a digital oscilloscope.

Rowlands JA, DeCrescenzo G.

Med Phys. 1990 Jan-Feb;17(1):58-64.

PMID:
2308547
33.

A light source for testing radiological television cameras.

Rowlands JA, Schulenburg KS, DeCrescenzo G.

Med Phys. 1989 Jan-Feb;16(1):1-6.

PMID:
2921966

Supplemental Content

Loading ...
Support Center